Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fred's, Inc. (NASDAQ:FRED),...

CNO : 20.52 (-0.24%)
NBIX : 94.64 (+0.60%)
FRED : 1.63 (+4.49%)
L : 50.14 (-1.10%)
KOS : 7.43 (unch)
NXST : 67.35 (+0.37%)
Neurocrine Biosc Set to Possibly Pullback After Yesterday's Rally of 2.94%

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $76.50 to a high of $83.51. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high...

NBIX : 94.64 (+0.60%)
DoubleLine Income Solutions Fund Declares May Distribution

LOS ANGELES , May 1, 2018 /PRNewswire/ -- DoubleLine Income Solutions Fund (the "Fund"), a closed-end fund traded on the New York Stock Exchange under the symbol DSL, today declared a distribution...

NBIX : 94.64 (+0.60%)
DSL : 19.97 (-0.15%)
Neurocrine Biosciences Reports First Quarter 2018 Financial Results

SAN DIEGO , April 30, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the first quarter 2018, and provided an update on the launch of INGREZZA...

NBIX : 94.64 (+0.60%)
ZYXI : 3.1000 (unch)
Neurocrine Biosciences Reports First Quarter 2018 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the first quarter 2018, and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development...

NBIX : 94.64 (+0.60%)
Neurocrine Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 30, 2018 at 5:00 PM Eastern...

NBIX : 94.64 (+0.60%)
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data for elagolix, an investigational, orally...

NBIX : 94.64 (+0.60%)
ABBV : 103.14 (-2.33%)
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions

SAN DIEGO , April 25, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration...

NBIX : 94.64 (+0.60%)
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive...

NBIX : 94.64 (+0.60%)
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 30, 2018. Neurocrine will then host a conference...

NBIX : 94.64 (+0.60%)
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results

SAN DIEGO , April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday,...

NBIX : 94.64 (+0.60%)
Insys Therapeuti is Among the Companies in the Biotechnology Industry with the Best Relative Performance (INSY , NBIX , IONS , ADMS , ARWR)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ARWR : 9.77 (unch)
NBIX : 94.64 (+0.60%)
INSY : 7.07 (-1.39%)
IONS : 45.23 (+2.59%)
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults...

NBIX : 94.64 (+0.60%)
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting

SAN DIEGO , April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA ® (valbenazine) capsules, the first U.S. Food and...

NBIX : 94.64 (+0.60%)
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain

AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced notification by the U.S. Food and Drug Administration...

NBIX : 94.64 (+0.60%)
ABBV : 103.14 (-2.33%)
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain

NORTH CHICAGO, Ill. , April 10, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:...

NBIX : 94.64 (+0.60%)
ABBV : 103.14 (-2.33%)
Watch for Neurocrine Biosc to Potentially Rebound After Falling 2.70% Yesterday

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $88.48 to a high of $92.46. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of...

NBIX : 94.64 (+0.60%)
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-II study (M12-817)...

NBIX : 94.64 (+0.60%)
ABBV : 103.14 (-2.33%)
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor...

NBIX : 94.64 (+0.60%)
Neurocrine Biosc Set to Possibly Pullback After Yesterday's Rally of 2.27%

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $84.85 to a high of $88.20. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high...

NBIX : 94.64 (+0.60%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar